Thoracic oncologists weigh how TROP2-directed antibody-drug conjugates fit into sequencing and combination strategies for EGFR-mutated NSCLC.
Commentary|Articles|October 21, 2026
Experts Tackle Key Questions on CDK4/6 Inhibition Across HR+ Breast Cancer Settings
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Breast cancer experts address frequently asked questions on adjuvant and metastatic CDK4/6 inhibitor selection in HR-positive breast cancer.
Advertisement
Advertisement
During an OncLive® State of the Science Summit™ on breast cancer held September 22, 2026, in Boston, Massachusetts, a faculty panel led by co-chairs Ana C. Garrido-Castro, MD, and Adrienne G. Waks, MD, both of Dana-Farber Cancer Institute, discussed optimal selection and integration of CDK4/6 inhibitor–based therapies in hormone receptor (HR)–positive breast cancer.
Related to this article
Faculty at an OncLive Scientific Interchange and Workshop discussed individualizing frontline immune checkpoint inhibitor selection in metastatic NSCLC.
The 510(k) clearance covers an MRI-derived AI risk score for stage I to IIIA disease; the high-risk category carried an HR of 2.81 for recurrence.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
Nunnery and Bond discuss how patients and advocates can navigate second opinions, mental health support, and the long-term effects of cancer treatment.
With multiple ADCs now available for use in gynecologic cancers, treatment decision-making incorporates biomarker nuances and raises sequencing questions.
Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.
Matthew P. Goetz, MD, explores menopausal status, recurrence risk, and adjuvant CDK4/6 inhibitor selection in HR-positive breast cancer.
Advertisement
Advertisement